Skip to main content

Table 2 Demographics and CSF biomarker profiles of sCAA patients and control subjects

From: Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients

 

Control (n = 28)

sCAA (n = 39)

p-Value

Age

71.44 (68.6–75.0)

72.3 (67.3–76.4)

0.93 (ns)

Sex (%M)

15/28 (54%)

24/39 (62%)

0.51 (ns)

Clinical markers

  

  MoCA

28 (27–29)

25 (21–28)

 < 0.001 (***)

  #CMB

0 (0–0)

9 (4–35)

 < 0.001 (***)

  SVD score

1 (1–1)

4 (4–5)

 < 0.001 (***)

CSF biomarkers

  

  Aβ40 (pg/mL)

12,507 (10,593–15,157)

7836 (6395–9404)

 < 0.001 (***)

  Aβ42 (pg/mL)

1075 (813–1314)

360 (287–449)

 < 0.001 (***)

  t-tau (pg/mL)

356 (276–496)

422 (282–559)

0.16 (ns)

  p-tau (pg/mL)

41.3 (32.5–61.8)

55.7 (35.4–70.4)

0.13 (ns)

  1. Data is presented as median (interquartile range). MoCA Montreal cognitive assessment; CMB Cerebral microbleed, SVD Small-vessel disease, p-tau Tau phosphorylated at threonine-181, t-tau Total tau. Student’s t-tests were performed for comparison of parametric data, Wilcoxon-signed rank tests for non-parametric data. ***p < 0.001, ns not significant
Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us